Ovid stock price target. 01% compared to the current stock price of $0.

Ovid stock price target. 21. 50 and a low forecast of $1. The upgrade comes as the stock Dec 30, 2024 · OVID Analysts' Consensus Rating The 8 analysts providing 12-month price projections for Ovid Therapeutics shares anticipate an average target of $3. Conversely, negative trial outcomes or Jun 5, 2025 · Ovid Therapeutics will host an event on June 12 discussing biomarkers in epilepsy and their OV329 drug development program. Aug 19, 2024 · Price Targets: Gaining insights, analysts provide estimates for the future value of Ovid Therapeutics's stock. Make informed investment decisions with our expert insights. 10 and trend of stock is towards upside and stock can be bought for price targets of 3. OVID stock price ended at $ 1. 00, although the firm maintained a Buy rating on the stock. 97. May 19, 2025 · Key Points Ovid's future hinges on the success of its clinical trials, specifically for its rare neurological disorder treatments. Stay updated on expert opinions and forecasts for OVID stock. 42, having declined about 87% over the past year. C. Ovid Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Ovid Therapeutics in the last 3 months, the avarage price target is $9. The upgrade comes as the stock trades near its 52-week low of $0. Throughout the last trading session, the stock experienced a fluctuation of 6. Conversely Sep 16, 2025 · The most recent analyst rating on (OVID) stock is a Buy with a $1. The average one-year price target for Ovid Therapeutics (NASDAQ:OVID) has been revised to 6. This average target implies a growth of 563. Get the latest Ovid Therapeutics Inc. Common Stock Price Forecasting Model To forecast the future price movements of Ovid Therapeutics Inc. Explore Ovid Therapeutics analyst ratings and price targets (NASDAQ:OVID) on Benzinga. Jan 29, 2025 · The average stock forecast for Ovid Therapeutics Inc (OVID) is 3. Start investing on Public. 50 price target. This is a potential upside of $5. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. HC Wainwright has a "Buy" rating and a $1. 21 and its nearest share price targets are 2. 40 with a high forecast of $5. The revision comes as the stock trades near its 52-week low of $0. 40 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold. 00 to Research Ovid Therapeutics' (Nasdaq:OVID) stock price, latest news & stock analysis. analyst ratings, historical stock prices, earnings estimates & actuals. Track OVID Stock with real-time price updates, overview, analysis, insider insights, and Smart Score ratings. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy. 6 days ago · Get detailed forecast and price target charts for Ovid Therapeutics Inc. 00% increase from the current stock price. 30 to a high estimate of $5. (OVID) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. 2 days ago · Explore Ovid Therapeutics stock price, quotes, charts and forecasts with Benzinga. This projected target price was predicated on several factors, including insiders selling, year over year drop in revenue, a month over month drop in Facebook fans, and a longterm decrease in Youtube subscribers. 6 days ago · Current and historical analyst ratings for Ovid Therapeutics (OVID) stock. 50-$5. (NASDAQ:OVID) with a Buy rating and Ovid Therapeutics Inc (1OT) Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for 1OT in the last 3 months. 00 with a stock forecast range of $1. OVID is trading at 1. The revision comes May 27, 2025 · This strategic shift led H. 07 (1690%) from yesterday's end of day stock price of $0. Discover Ovid Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Wainwright have adjusted their price target for Ovid Therapeutics (OVID, Financial), reducing it from $2 to $1. 51. 2 days ago · Price Target Based on short-term price targets offered by 43 analysts, the average price target for Nvidia comes to $213. 21 and trend of stock is towards downside and stock can be sold for price targets of 2. Mar 16, 2025 · Key Points Ovid Therapeutics faces an uncertain future. 38 / share. 16 to a day high of 1. 29, with estimates ranging from $3. Get Ovid Therapeutics news, earnings, and stock analysis — all in one place at TipRanks. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page. OVID updated stock price target summary. 46) EPS. Mar 26, 2025 · Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4. 6524. Pipeline setbacks or clinical trial failures could severely diminish investor confidence and lead to significant stock price declines. 00 and a low estimate of $2. 2 on downside and 2. 01 and its nearest share price targets are 1. May 28, 2025 · n:Time series to forecast p:Price signals of Ovid Therapeutics stock j:Nash equilibria (Neural Network) k:Dominated move of Ovid Therapeutics stock holders a:Best response for Ovid Therapeutics target price For further technical information as per how our model work we invite you to visit the article below: Stock listed under Health Care Top price targets Weekly price targets Monthly price targets Yearly price targets Intraday price targets As on 08 Fri Dec 2023 Current price of Ovid Therapeutics Inc. View live Ovid Therapeutics Inc. 26 and trend of stock is towards upside and stock can be bought for price targets of 3. Mar 24, 2025 · On Monday, BTIG analyst Thomas Shrader revised the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $4. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. 00 and set a “buy” rating on the stock in a report on Monday, March 24th. Get the latest Ovid Therapeutics Inc (OVID) stock analyst ratings and price targets from StockTargetAdvisor. Conversely, failure in clinical trials or setbacks in regulatory submissions, such as In other recent news, Ovid Therapeutics Inc has seen an upgrade in its stock rating from Perform to Outperform by Oppenheimer analyst Francois Brisebois, who has also set a new price target at $4. What is the analyst price target for Ovid Therapeutics (OVID)? Wall Street analysts have set a price target of $5. 47 USD. Common Stock (OVID). 76, 1. 5 days ago · Should You Buy or Sell Ovid Therapeutics Stock? Get The Latest OVID Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. May 27, 2025 · Wall Street Analysts Forecast Based on the one-year price targets offered by 5 analysts, the average target price for Ovid Therapeutics Inc (OVID, Financial) is $3. 50 from 10 Wall St analysts. May 27, 2025 · On Tuesday, H. Shrader Jan 3, 2025 · Ovid Therapeutics (OVID) stock forecast & analyst price target predictions based on 25 analysts offering 12-months price targets for OVID in the last 3 months. Much of this optimism surrounds the company’s OV329, which is anticipated to achieve $1 billion in 1 day ago · Complete Ovid Therapeutics Inc. BTIG Research cut their price objective on Ovid Therapeutics from $5. Real-time charts, technical indicators, price targets, and financial data for informed investing. Jan 29, 2025 · On Wednesday, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ: OVID) from Perform to Outperform, establishing a price target of $4. . 75, with the highest OVID stock price forecast at $4. 00, while maintaining a Buy rating on Based on 7 Wall Street analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. However, the company is expected to achieve several key value milestones within the next year, positioning it for potential growth. 41, 3. Find everything from its Valuation, Future Growth, Past Performance and more. OVID - Ovid Therapeutics Inc - Stock screener for investors and traders, financial visualizations. OVID Stock 12 Month Analyst Forecast According to evaluations from 7 analysts over the past year, the consensus analyst rating for OVID stock is "Buy". (OVID) stock, including real-time price, chart, key statistics, news, and more. 26, 3. 40) per share. 3. 50 USD and a high forecast of 5. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which Ovid Therapeutics Inc. Shrader Aug 25, 2025 · Learn how to buy Ovid Therapeutics Inc. Stay ahead of the game with our OVID stock price prediction for 2025 and 2026 to 2030. According to 2 Wall Street analyst s that have issued a 1 year OVID price target, the average OVID price target is $2. OVID share price target tomorrow IntraDay As on 11 Fri Nov 2022 Ovid Therapeutics Inc. The price target for Ovid Therapeutics, Inc. stock news by MarketWatch. The company's reliance on a limited number of drug candidates and partnerships presents concentration risk; the loss of a key partnership or failure of a single product could be devastating. 31, ranging from a low estimate of $1. 20 with a high estimate of $4. 63% from the current price of $0. 75, 3. Currently trading at $0. 73. 00, while retaining a Buy rating on the stock. The firm notes the company’s management 5 days ago · OVID | Complete Ovid Therapeutics Inc. This comparison reveals trends in analysts' expectations over time. View Ovid Therapeutics Inc. OVID is 3. The average price target based on the past year stands at $3. OVID Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Ovid Therapeutics Inc News. May 27, 2025 · This strategic shift led H. Mar 24, 2025 · Meanwhile, Ovid expanded its Board of Directors, appointing Stelios Papadopoulos, Ph. 50. 03 and its nearest share price targets are 1. 96 on downside and 2. Stock Target Advisor’s own stock analysis of Ovid Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. Riley reissued a "buy" rating and issued a $3. The model leverages a comprehensive dataset encompassing various factors potentially influencing OVID's stock Jan 29, 2025 · On Wednesday, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ: OVID) from Perform to Outperform, establishing a price target of $4. 35% increase from the current price of $1. The highest analyst price target is $9. In other recent news, Ovid Therapeutics Inc has seen an upgrade in its stock rating from Perform to Outperform by Oppenheimer analyst Francois Brisebois, who has also set a new price target at $4. 00 price target on shares of Ovid Therapeutics in a report on Friday, August 8th. Finally, HC Wainwright decreased their price objective on shares of Ovid Therapeutics from $2. 00, down from the previous $5. 50, down from the previous $2. 9, 3. 00, while maintaining a Buy rating on the company’s stock. 50 and set a "buy" rating on the stock in a research report on Tuesday, May 27th. The model utilizes a variety of factors, including historical stock data (trading volume, volatility, and past price movements), financial statements (revenue, earnings per share, debt levels, cash May 27, 2025 · On Tuesday, H. Positive results from ongoing trials, particularly for its pipeline candidates targeting neurological disorders, could trigger significant stock price appreciation. Ovid Therapeutics stock price interactive chart, yearly historical data, price target, split dates, performance comparison to indexes and ETFs Looking to buy Ovid Therapeutics Stock? Get the latest OVID quote, news, earnings, forecast, price targets, and market insights. (NASDAQ:OVID) with a Buy rating and Get the latest Ovid Therapeutics stock forecast for tomorrow and next week. The average target implies an upside of 1,021. 37. 00. The revision comes Expert stock analysis of OVID (OVID). sales within five years, targeting epilepsy and May 31, 2025 · OVID Stock Forecast Model Our data science and economics team has developed a comprehensive machine learning model to forecast the future performance of Ovid Therapeutics Inc. Is OVID a Buy, Sell or Hold? Based on May 27, 2025 · Analysts at H. D. (OVID) shares with our complete investment analysis including price forecasts, risks, and step-by-step purchasing guide. Wainwright to lower its 12-month price target for Ovid Therapeutics from $3. (OVID), a multi-disciplinary team of data scientists and economists developed a machine learning model. 00, while the lowest price target for OVID is $1. 15 on upside. See Ovid Therapeutics Inc. 29% from the prior estimate of 5. chart to track its stock's price action. Create real-time notifications to follow any changes in the live stock price. HC Wainwright also issued estimates for Ovid Therapeutics' FY2025 earnings at ($0. (NASDAQ: OVID) is highlighted as one of the best US stocks under $10, with analysts giving it a Buy rating and a price target of $5. " What is the target price for Ovid Therapeutics? On May 20, an AI target price of Premium - Sign up was allocated to Ovid Therapeutics (OVID). 68, with InvestingPro data showing the shares have declined over 80% in the past year. over the next 1-year time period is forecast to be $3. (NASDAQ:OVID) with a Buy rating and The Ovid Therapeutics Inc (OVID) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $8. OVID Analysts' Consensus Rating The 7 analysts providing 12-month price projections for Ovid Therapeutics shares anticipate an average target of $3. Despite this revision, they maintain a Buy rating on the stock. 1 day ago · Stock forecasts and analyst price target predictions for NVIDIA Corporation (NVDA) stock, with detailed revenue and earnings estimates. 094 USD. 4% compared to the current stock price of $0. Aug 25, 2025 · Discover Ovid Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Find market predictions, OVID financials and market news. Find the latest Ovid Therapeutics Inc. View (OVID) real-time stock price, chart, news, analysis, analyst reviews and more. The forecasts range from a low of $100. At the last closing, Ovid Therapeutics Inc’s stock price was USD 0. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0. Sep 14, 2025 · Ovid (OVID) has a price target of $3. 00 to $4. The range of stock forecasts for OVID is 1. S. Shrader May 27, 2025 · This strategic shift led H. US updated stock price target summary. OVID. 51 - 5. In analyst news, Oppenheimer upgraded Ovid’s stock rating from Perform to Outperform, setting a price target of $4. (NasdaqGS) - Forecast, Price Target, Estimates, PredictionsThis card shows analyst upgrades/downgrades for Ovid Therapeutics Inc. 21 on Friday, after losing -0. 55 on downside and 1. Jul 22, 2025 · OVID has been the topic of a number of research reports. 2 days ago · Check if OVID Stock has a Buy or Sell Evaluation. Aug 13, 2025 · Detailed statistics for Ovid Therapeutics Inc. View today's Ovid Therapeutics Inc stock price and latest OVID news and analysis. 95, 1. 50 price target on the stock. 2 days ago · Based on short-term price targets offered by four analysts, the average price target for Ovid Therapeutics comes to $2. Over the past six months, its share price has outperformed the S&P500 Index by +23. 00 price target on the stock in a research note on Wednesday, January 29th. Stay updated on market trends for OVID. 97, reflecting a 0. 9816, and the lowest is $6. William Blair upgraded Ovid Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. 92 USD with a low forecast of 0. 66 on upside. Sep 2, 2025 · A detailed overview of Ovid Therapeutics Inc. 3, 3. According to InvestingPro analysis, the stock appears undervalued at current levels. The most recent analyst rating on (OVID) stock is a Buy with a $4. According to Wall Street analysts, the average 1-year price target for OVID is 2. The primary prediction is that positive trial results could lead to significant stock price appreciation, fueled by increased investor confidence and potential acquisition interest from larger pharmaceutical companies. Feb 8, 2025 · OVID Therapeutics Inc. 64. Click here to see the forecast for OVID stock OVID / Ovid Therapeutics Inc. OVID share price target tomorrow IntraDay As on 13 Mon Mar 2023 Ovid Therapeutics Inc. Product Focus: The company's optimism is largely based on its product OV329, expected to generate $1 billion in U. The standard analyst ratings are See Ovid Therapeutics Inc. 22, 2. Get latest news and stock predictions. OVID : Ovid Therapeutics stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical Analysis Ovid Therapeutics Inc has a share price target of US$ 3, revenue growth forecast of 1075. The Trend in the Analyst Price Target Over the past 20 months, OVID's average price target has gone up $2. 35 and trend of stock is towards downside and stock can be sold for price targets of 3. As on 06 Wed Apr 2022 Current price of Ovid Therapeutics Inc. 78 USD. 88. View real-time stock prices and stock quotes for a full financial overview. Ovid Therapeutics stock forecast report. (OVID) stock. What is the trend in the Ovid Therapeutics share price? An important predictor of whether a stock price will go up is its track record of momentum. 5% for FY25, based on top 7 analyst calls. 20 to a high estimate of $5. The forecasts range from a low of $1. A high-level overview of Ovid Therapeutics Inc. 4%, and profit growth estimate of -36. 5, with a high forecast of $11. Jun 5, 2025 · Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program HighlightsNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. Current price: . OVID reports an average of 75. The price target for Ovid Therapeutics over the next 1-year time period is forecast to be $3. OVID stock quote prices, financial information, real-time forecasts, and company news from CNN. 28 with a market capitalization of $20. This is an increase of 10. stock on Seeking Alpha. What is the current stock price of Ovid Therapeutics (OVID)? The current stock price of Ovid Therapeutics (OVID) is $1. 08 on upside. Wainwright analyst Raghuram Selvaraju adjusted the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $1. The best long-term & short-term Ovid Therapeutics share price prognosis for 2023, 2024, 2025, 2026, 2027, 2028 with daily OVID exchange price projections: monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis Feb 19, 2025 · The latest Ovid Therapeutics stock prices, stock quotes, news, and OVID history to help you invest and trade smarter. 10. 41 Mar 24, 2025 · On Monday, BTIG analyst Thomas Shrader revised the price target for Ovid Therapeutics Inc (NASDAQ: OVID) to $4. The average 4 days ago · The 4 analysts that cover Ovid Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $3. 1, 2. 01% compared to the current stock price of $0. The average price target represents a 1207. 60 and its nearest share price targets are 1. (OVID) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. HC Wainwright lowered their target price on Ovid Therapeutics from $2. 317, representing a +587. 23 to 1. 03, 1. Based on the ratings of 13, the consensus recommendation for OVID is BUY Ovid Therapeutics Inc. 13, which forecasts a 158. 00 to a high of $250. OVID is currently trading with a negative enterprise value. The upgrade comes as the stock As on 07 Thu Jul 2022 Current price of Ovid Therapeutics Inc. stock information by Barron's. Shrader Jan 29, 2025 · On Wednesday, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ: OVID) from Perform to Outperform, establishing a price target of $4. , as a new member, and updated its compensation policy for non-employee directors. 88% , ranging from a day low of $1. 97%. 50, reflecting a potential surge of nearly 467% from the current price. 00 to $1. 00 to $2. 68%. The high price target for OVID is $27. This average target implies a growth of 236. Ovid Therapeutics Inc. 31 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold. 21 as of September 19, 2025. 00 and the low price target for OVID is $10. 99 Aug 7, 2025 · Quarterly revenue - Rate of surprise Company calendar Stock Market Equities OVID Stock 1OT Stock Consensus Ovid Therapeutics Inc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months. Investment Potential: Ovid Therapeutics Inc. 02 On Wednesday, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ: OVID) from Perform to Outperform, establishing a price target of $4. 50 to a high of $4. 68% increase in the stock price over the next year. 38, ranging from a low estimate of $1. (NASDAQ:OVID) with a Buy rating and a price target of $5. (OVID) stock quote, history, news and other vital information to help you with your stock trading and investing. Sep 7, 2025 · B. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ovid Therapeutics. (OVID) stock, including valuation metrics, financial numbers, share information and more. Stock listed under Health Care Top price targets Weekly price targets Monthly price targets Yearly price targets Intraday price targets As on 14 Fri Apr 2023 Current price of Ovid Therapeutics Inc. Jun 15, 2025 · Key Points Ovid's stock faces considerable volatility due to its reliance on clinical trial outcomes and the potential for regulatory approvals. (NASDAQ: OVID), a View live Ovid Therapeutics Inc. Wall Street analysts forecast OVID stock price to rise over the next 12 months. The highest price target for OVID is $4. 00 price target. 00 and the lowest OVID stock price forecast at $1. Where is Ovid Therapeutics stock heading? Wall Street analysts weigh in with their latest ratings and OVID price targets at PriceTargets. View OVID price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data. OVID share price target tomorrow IntraDay As on 21 Thu Jul 2022 Ovid Therapeutics Inc. 50, indicating a potential increase of nearly 467%. 24 on upside. Mar 12, 2025 · Wedbush analyst Laura Chico lowered the firm’s price target on Ovid Therapeutics (OVID) to $3 from $4 and keeps an Outperform rating on the shares. Price target in 14 days: 1. This price target corresponds to an upside of 198. OVID is trading at 2. OVID is currently covered by 1 analysts with an average price target of $5. The average price target is $3. 29 million, InvestingPro analysis suggests the stock is undervalued relative to its Fair Value. 50 USD. 82% The Ovid Therapeutics Inc stock price decreased by -0. com. 59 The Latest Ovid Therapeutics Inc (OVID) Stock Price, News, Catalysts, Short Interest, Volume, Target Price, and Company Information. The . View real-time OVID stock price and news, along with industry-best analysis. 29. (NasdaqGS:OVID) stock price, share price history, and explore other investor’s opinions to make your investment decision. 2398. (NASDAQ: OVID) is among the best US stocks under $10 to invest in. OVID share price target tomorrow IntraDay As on 10 Wed Aug 2022 Ovid Therapeutics Inc. 78 dated October 4, 2023. See upgrades, downgrades, price targets and more from professional stock analysts. 81% change from the last price of $0. 5 days ago · According to the 6 analysts' twelve-month price targets for Ovid Therapeutics, the average price target is $3. 82% on the last trading day (19 Sep 2025), dropping from 1. Aug 23, 2025 · Ovid Therapeutics Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. 42% for its upside potential over the past 40 weeks. OVID is 2. Find the latest Ovid Therapeutics Inc (OVID) stock forecast, 12-month price target, predictions and analyst recommendations. lvh mjpq kezl afdaq tbclgvx prhijv egl ljfvx gjm wjrzhlbg